The Discovery of Target Antigens for Dysfunctional T Cells in ME/CFS and Long COVID
Dr. Liisa Selin, Dr. Ayano Kohlgruber, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst Award for their study searching for the exact proteins recognized by T-cell receptors from a […]
GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar […]
Solve CEO Emily Taylor Reflects On What We Built Together In 2025 and Why It Mattered
Dear Friends, As this year comes to a close, I find myself thinking not just about what we accomplished — but why it mattered. As a caregiver who understands how […]
Simmaron’s Solve ME/CFS Catalyst Award-Winning Rapamycin Trial Yields Promising Treatment Findings
Dr. Avik Roy is the chief scientific officer at the Simmaron Research Institute, a non-profit organization dedicated to understanding ME/CFS and related diseases and to treating people with these diseases. […]
Targeting Autophagy: A Clinical Trial of Low-Dose Rapamycin for ME/CFS, Long COVID, and IACCIs
Simmaron Research is the second recipient of Solve’s ME/CFS Catalyst Award in support of its study,” “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” Read a preprint […]
Solve Selects Simmaron Research As Recipient of ME/CFS Catalyst Award to Accelerate Low-Dose Rapamycin Trial for ME/CFS, Long COVID, and IACCs
Dr. C. Gunnar Gottschalk and Dr. Avik Roy Solve M.E. is proud to announce that we’ve selected the Simmaron Research Institute as the winner of our second Solve ME/CFS Catalyst […]
Trailblazing Researcher Dr. Akiko Iwasaki Receives Inaugural ME/CFS Catalyst Award from Solve M.E.
Dr. Akiko Iwasaki In honor of World ME Day, we are proud to announce the Solve ME/CFS Catalyst Awards—a focused initiative designed to keep momentum alive for promising scientific work […]